Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.
Advertisement
Articles by Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
2
Amid SOHO Data, Reviewers of BTK Inhibitors in MCL Call for Trials
3
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
4
Counseling Vitiligo Patients on Time to Repigmentation
5